AstraZeneca (AZN.US) monoclonal antibody new drug approved for two indications in China
AstraZeneca (AZN.US) announced the official launch of Tezelyumab injection in China.
Zhitong Finance APP has learned that on August 17, AstraZeneca (AZN.US) announced the official launch of Tezepelumab injection in China. Tezepelumab is a biologic used to treat severe asthma, overcoming phenotype and biomarker level restrictions, and targets thymic stromal lymphopoietin (TSLP).
In March 2026, based on positive results from the DIRECTION and WAYPOINT Phase III clinical studies, Tezepelumab was approved in China for two indications: maintenance treatment for severe asthma in adults and adolescents aged 12 years and above; and, in combination with intranasal corticosteroids, for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients whose disease cannot be adequately controlled with systemic corticosteroids and/or surgery.
Tezepelumab is a human monoclonal antibody jointly developed by AstraZeneca and Amgen, capable of inhibiting the activity of TSLP. TSLP is a key epithelial cytokine upstream of multiple inflammatory cascades, playing a crucial role in the initiation and persistence of allergic, eosinophilic, and epithelium-driven inflammation associated with severe asthma, chronic rhinosinusitis with nasal polyps, and other inflammatory diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The “outlier” in the AI capital expenditure frenzy: Apple (AAPL.US) keeps spending flat, accounting for less than 5% of sales
Apple continues to stand out among major tech peers, largely avoiding the aggressive wave of capital expenditure associated with artificial intelligence (AI) infrastructure.
Youth Employment Declines for 48 Consecutive Months: Behind the Semiconductor Boom, Young South Koreans Are Being Left Behind by the Times
In South Korea, the unemployment rate in October fell to a three-year low of 2.5%. However, the number of employed people decreased by 50,000, youth employment has declined for 48 consecutive months, and domestic demand remains weak.
Strategy (MSTR.US) Faces Potential Removal from MSCI Index, Passive Funds May Sell $2.8 Billion
MicroStrategy is expected to be removed from the MSCI Global Investable Market Index. JPMorgan estimates that passive funds may sell about $2.8 billion worth of shares, and if removed from multiple indexes simultaneously, the scale could reach up to $8.8 billion. Additionally, with BTC falling below its average cost of $75,456, the company’s stock price and financing capacity are under dual pressure.
Crypto prices
More
